Recent Updates
Recently added Catalysts
HROW Positive Sentiment Score: 70/100

Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026

Key Takeaway: Harrow (Nasdaq: HROW) announced it will report its first quarter 2026 financial results on May 11, 2026, after market close. A conference call and webcast will follow on May 12, 2026, at 8:00 a.m. ET for discussing the results and providing updates. The company emphasizes its dedication to ophthalmic disease management.

Market Sentiment Analysis

POSITIVE FACTORS

  • Harrow is set to report its first quarter financial results, indicating ongoing business activity.
  • The company continues to engage with investors through a conference call and webcast.
  • Harrow's commitment to ophthalmic disease management solutions highlights its focus on improving patient care.

Full Press Release Details

NASHVILLE, Tenn., April 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the first quarter ended March 31, 2026, on Monday, May 11, 2026, after the market close. The Company will also post its first quarter Letter to Stockholders to the “Investors” section of its website,harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, May 12, 2026, to discuss the results and provide a business update.
Conference Call InformationParticipants can access thelive webcastof Harrow’s presentation on the “Investors” page of Harrow’s website. A replay of the webcast will be available on the Company’s website for one year.
To participate via telephone, please register in advance using thislink. Upon registration, all telephone participants will receive a confirmation email with detailed instructions, including a unique dial-in number and PIN, for accessing the call.
About HarrowHarrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visitharrow.comand connect with us onLinkedIn.

Contact:Mike BiegaVP of Investor Relations & Communicationsmbiega@harrowinc.com617-913-8890

Frequently Asked Questions

When will Harrow report its Q1 2026 financial results?

Harrow will report its Q1 2026 financial results on May 11, 2026.

What time is the conference call for Harrow's financial results?

The conference call will take place on May 12, 2026, at 8:00 a.m. ET.

Where can I find the webcast of Harrow's presentation?

The webcast will be available on the 'Investors' page of Harrow's website.

How can I participate in the conference call?

Participants must register in advance to receive a unique dial-in number and PIN.

Last updated: Apr 27, 2026